Related Experiment Video

Updated: Oct 5, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation

Yunjiao Zhou1, Zhenwei Yang1, Hailin Zhang1

  • 1Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China; Hubei Clinical Center and Key Lab of Intestinal and Colorectal Diseases, Wuhan, Hubei 430071, China.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|January 22, 2022
PubMed

Insights

DNA methyltransferase 3A (DNMT3A) promotes colorectal cancer (CRC) by epigenetically silencing the tumor suppressor DAB2IP, activating the MEK/ERK pathway. This finding offers potential new therapeutic targets for CRC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Tumor suppressor DOC-2/DAB2 interactive protein (DAB2IP) inactivation is implicated in human cancers.
  • DNA methyltransferase 3A (DNMT3A) is crucial for DNA methylation and tumorigenesis.
  • The role of DNMT3A in regulating DAB2IP in colorectal cancer (CRC) progression was previously unknown.

Purpose of the Study:

  • To investigate the role of DNMT3A in CRC progression.
  • To elucidate the mechanism by which DNMT3A affects DAB2IP expression and signaling pathways.
  • To identify potential therapeutic targets for CRC.

Main Methods:

  • Analysis of DNMT3A expression in CRC tissues and correlation with patient survival.
  • Cell proliferation and cell cycle arrest assays upon DNMT3A manipulation.
  • Methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP) to assess DAB2IP promoter methylation.
  • Dual-luciferase reporter and ChIP-PCR assays to confirm DNMT3A binding to the DAB2IP promoter.
  • Western blotting to analyze MEK/ERK pathway activation.
  • Inhibition of MEK/ERK signaling to evaluate its role in DNMT3A-induced oncogenesis.

Main Results:

  • DNMT3A expression is elevated in CRC and associated with poor survival.
  • DNMT3A overexpression enhances CRC cell proliferation; knockdown induces cell cycle arrest.
  • DNMT3A epigenetically suppresses DAB2IP via promoter methylation and directly binds to the DAB2IP promoter.
  • DNMT3A downregulates DAB2IP, leading to activation of the MEK/ERK pathway.
  • Inhibiting the MEK/ERK pathway reverses the oncogenic effects of DNMT3A.

Conclusions:

  • DNMT3A drives CRC progression by epigenetically silencing DAB2IP and activating the MEK/ERK pathway.
  • DNMT3A-mediated regulation of DAB2IP and MEK/ERK signaling represents a potential therapeutic strategy for CRC.
Keywords:
Colorectal cancerDAB2IPDNA methylationDNMT3AMEK/ERK signaling

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K